Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 2;39(3):404-410.
doi: 10.46497/ArchRheumatol.2024.10410. eCollection 2024 Sep.

Association of focus score and extraglandular involvement in Sjögren's syndrome: A study on antinuclear antibodies and minor salivary gland pathology

Mustafa Çağrı Ergün  1 , Okancan Yılmaz  2 , Hakan Bilgen  3 , Pembe Oltulu  2 , Fahriye Kılınç  2 , Recep Tunç  1
Affiliations

Association of focus score and extraglandular involvement in Sjögren's syndrome: A study on antinuclear antibodies and minor salivary gland pathology

Mustafa Çağrı Ergün et al. Arch Rheumatol. .

Abstract

Objectives: This study aimed to investigate the relationship between patients with and without extraglandular involvement in Sjögren's syndrome (SS) by analyzing ANA (antinuclear antibody) and ENA (extractable nuclear antigen) results and minor salivary gland pathology findings.

Patients and methods: A total of 265 (245 females; 20 males; mean age: 50.4±12.4; range, 19 to 79 years) patients diagnosed with SS were included in the retrospective cohort study between March 1, 2011, and December 1, 2021. Detailed documentation was performed, capturing demographic characteristics, clinical information, laboratory findings, medication usage, and manifestations of the syndrome. The patients were divided into two groups, with (78 females; 8 males; mean age: 52.7±11.5; range, 22 to 78 years or without (167 females; 12 males; mean age: 49.3±12.8; range, 19 to 79 years extraglandular involvement.

Results: The mean follow-up duration was 63.1±31.9 months. Extraganular involvement, including joint involvement, lung involvement, central nervous system involvement, hematological involvement, hepatitis, and lymphoma, was observed in 32.5% of the patients. Patients with extraglandular involvement required multiple medications, while those with only glandular involvement predominantly used hydroxychloroquine. The mean duration from SS diagnosis to extraglandular involvement was 15.2±27.8 months. The comparison between patients with and without extraglandular involvement revealed a significant association between higher focus scores (FS) and extraglandular manifestations. However, no significant differences were observed in terms of ANA positivity, ANA titers, or ENA positivity. Regression analysis indicated that age and FS were linked to systemic involvement.

Conclusion: This study highlights the importance of FS as a predictive indicator for extraglandular manifestations in SS. Advanced age was found to be associated with an increased likelihood of extraglandular involvement. Assessing FS and age can aid in predicting extraglandular manifestations.

Keywords: Antinuclear antibodies; Sjögren's syndrome; extraglandular involvement; focus score; systemic manifestations..

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.

References

    1. Navarro-Mendoza EP, Aguirre-Valencia D, PossoOsorio I, Correa-Forero SV, Torres-Cutiva DF, Loaiza D, et al. Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sjögren’s syndrome. Autoimmun Rev. 2018;17:709–714. doi: 10.1016/j.autrev.2018.02.003. - DOI - PubMed
    1. Jonsson R, Theander E, Sjöström B, Brokstad K, Henriksson G. Autoantibodies present before symptom onset in primary Sjögren syndrome. JAMA. 2013;310:1854–1855. doi: 10.1001/jama.2013.278448. - DOI - PubMed
    1. Christodoulou MI, Kapsogeorgou EK, Moutsopoulos HM. Characteristics of the minor salivary gland infiltrates in Sjögren’s syndrome. J Autoimmun. 2010;34:400–407. doi: 10.1016/j.jaut.2009.10.004. - DOI - PubMed
    1. Fauchais AL, Ouattara B, Gondran G, Lalloué F, Petit D, Ly K, et al. Articular manifestations in primary Sjögren’s syndrome: Clinical significance and prognosis of 188 patients. Rheumatology (Oxford) 2010;49:1164–1172. doi: 10.1093/rheumatology/keq047. - DOI - PubMed
    1. Willeke P, Schlüter B, Becker H, Schotte H, Domschke W, Gaubitz M. Mycophenolate sodium treatment in patients with primary Sjögren syndrome: A pilot trial. R115Arthritis Res Ther. 2007;9 doi: 10.1186/ar2322. - DOI - PMC - PubMed

LinkOut - more resources